$DERM
Journey Medical Corporation
A volume-weighted average price line from the last reported earnings date through today.
About Journey Medical Corporation
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
- CEO
- Mr. Claude Maraoui
- Employees
- 58
- Headquarters
- Scottsdale, AZ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Website
- journeymedicalcorp.com
Key stats
- Market Cap
- $209.14M
- P/E Ratio
- —
- Avg Volume (3M)
- 244.67K
- EPS
- -$0.22
- Day's Range
- $7.25 – $7.49
Fundamentals as of Sep 01, 2026